Journals / Türk Kardiyoloji Derneği Arşivi / 2019 / Cilt: 47 - Sayı: 2

Cardiac amyloidosis: Recent advances in the diagnosis and therapy

Kardiyak amiloidoz: Tanı ve tedavide yenilikler

Pages
1–34
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The aim of this paper is to provide a comprehensive review including etiology, clinical presentation, diagnosis and management of CA and to address recent important advances in noninvasive cardiac imaging techniques and novel therapeutic approaches based on the available data in the literature.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Cardiac amyloidosis (CA) is a progressive cardiomyopathy in which misfolded endogenous proteins form amyloid fibrils that deposit in the heart as well as kidneys, liver, gastrointestinal tract and soft tissues.
📊
Key Findings & Data:Although cardiac amyloidosis is thought to be a very rare disease, emerging data suggested that 13% of heart failure patients with preserved ejection fraction and 16–26% of advanced aged patients with severe aortic stenosis may have TTR-CA.
💡
Conclusion & Impact:The aim of this paper is to provide a comprehensive review including etiology, clinical presentation, diagnosis and management of CA and to address recent important advances in noninvasive cardiac imaging techniques and novel therapeutic approaches based on the available data in the literature.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Cardiac amyloidosis (CA) is a progressive cardiomyopathy in which misfolded endogenous proteins form amyloid fibrils that deposit in the heart as well as kidneys, liver, gastrointestinal tract and soft tissues. The most common forms of CA include immunoglobulin light chain (AL) amyloidosis and transthyretin (TTR) amyloidosis. Although cardiac amyloidosis is thought to be a very rare disease, emerging data suggested that 13% of heart failure patients with preserved ejection fraction and 16–26% of advanced aged patients with severe aortic stenosis may have TTR-CA. Amyloidosis with cardiac involvement shows poor prognosis with a median survival of 6 months in AL-CA and 26–43 months in TTR-CA. Early diagnosis and novel therapeutic options have been shown to significantly improve prognosis. Recent diagnostic techniques such as cardiac MR or nuclear scintigraphy using bone isotopes as well as increasingly wide use of echocardiography, genetic testing, biopsy and histopathological analysis allow the clinicians to make early diagnosis of CA. The aim of this paper is to provide a comprehensive review including etiology, clinical presentation, diagnosis and management of CA and to address recent important advances in noninvasive cardiac imaging techniques and novel therapeutic approaches based on the available data in the literature.

Özet

Kardiyak amiloidoz (KA), katlanması bozulan endojen proteinlerin amiloid fibrilleri şeklinde kalpte ve çoğunlukla beraberinde böbrek, karaciğer, gastrointestinal sistem ve yumuşakdokuda birikmesi sonucu ortaya çıkan ilerleyici bir kardiyomiyopati olarak kabul edilir. En sık gözlenen KA formları, immunglobulin hafif zincir (AL) amiloidozu ve transtretin (TTR)amiloidozudur. Bugüne kadar KA oldukça nadir görülen birhastalık olarak düşünülmüş olsa da çok yeni veriler korunmuş ejeksiyon fraksiyonlu kalp yetersizliği olgularının %13 veyüksek riske sahip ciddi aort darlığı bulunan yaşlı olguların%16–26’sında TTR-KA bulunduğunu göstermektedir. Kardiyak tutulumun bulunduğu amiloidozda prognoz kötü olupAL KA’da ortalama survi 6 ay ve TTR-KA’da ortalama survi26–43 ay bildirilmektedir. Erken tanı ve tedavi yaklaşımları ileprognozun anlamlı düzeltilebildiği gösterilmiştir. Kardiyak MRve nükleer kemik sintigrafisi gibi yeni tanısal teknikler ile beraber gittikçe kullanımı yaygınlaşan ekokardiyografi, genetikanaliz, biopsi ve histopatolojik testler klinisyene KA’nın erkentanı olanağını vermektedir. Bu belge, KA etiyolojisi, klinik bulguları, tanı ve yönetimine ilişkin kapsamlı bir değerlendirmeile beraber noninvaziv kardiyak görüntüleme ve yeni tedaviyaklaşımlarıyla ilgili önemli gelişmeleri mevcut verilere dayanarak ele almaktadır

🔖

Cite This Article

TÜFEKÇİOĞLU, O., TOKGÖZOĞLU, L., KAYIKÇIOĞLU, M., ÇELİK, A., İKİTİMUR, B., ÇAVUŞOĞLU, Y., ÖZPELİT, E., YILMAZ, M. B. (2022). Cardiac amyloidosis: Recent advances in the diagnosis and therapy. Türk Kardiyoloji Derneği Arşivi, Cilt: 47 - Sayı: 2, 1–34. https://ajindex.com/articles/632070

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Parry TL, Melehani JH, Ranek MJ, Willis MS. Functional amyloid signaling via the inflammasome, necrosome, and signalosome: new therapeutic targets in heart failure. Front Cardiovasc Med 2015;2:25
  2. Sipe JD, Cohen AS. Review: history of the amyloid fibril. J Struct Biol 2000;130:88–98
  3. Guan J, Mishra S, Falk RH, Liao R. Current perspectives on cardiac amyloidosis. Am J Physiol Heart Circ Physiol 2012;302:H544–52
  4. Mankad AK, Shah KB. Transthyretin cardiac amyloidosis. Curr Cardiol Rep 2017;19:97
  5. Gertz MA, Dispenzieri A, Sher T. Pathophysiology and treatment of cardiac amyloidosis. Nat Rev Cardiol 2015;12:91–102
  6. Gertz MA. Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018. Blood Cancer J 2018;8:44
  7. Milani P, Merlini G, Palladini G. Light chain amyloidosis. Mediterr J Hematol Infect Dis 2018;10:e2018022
  8. Saraiva MJ. Transthyretin mutations in health and disease. Hum Mutat 1995;5:191–6
  9. Sattianayagam PT, Hahn AF, Whelan CJ, Gibbs SD, Pinney JH, Stangou AJ, et al. Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. Eur Heart J 2012;33:1120–7
  10. Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C, et al. Wildtype transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 2015;36:2585–94
  11. Rapezzi C, Quarta CC, Obici L, Perfetto F, Longhi S, Salvi F, et al. Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart J 2013;34:520–8
  12. Pukitis A, Zake T, Groma V, Ostrovskis E, Skuja S, Pokrotnieks J. Effect of infliximab induction therapy on secondary systemic amyloidosis associated with Crohn’s disease: case report and review of the literature. J Gastrointestin Liver Dis 2013;22:333–6
  13. Louros NN, Iconomidou VA, Tsiolaki PL, Chrysina ED, Baltatzis GE, Patsouris ES, Hamodrakas SJ. An N-terminal proatrial natriuretic peptide (NT-proANP) ‘aggregation-prone’ segment involved in isolated atrial amyloidosis. FEBS Lett 2014;588:52–7
  14. Podduturi V, Armstrong DR, Hitchcock MA, Roberts WC, Guileyardo JM: Isolated atrial amyloidosis and the importance of molecular classification. Proc (Bayl Univ Med Cent) 2013;26:387–9
  15. Mohammed SF, Mirzoyev SA, Edwards WD, Dogan A, Grogan DR, Dunlay SM, et al. Left ventricular amyloid deposition in patients with